Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X Syndrome: an N-of-1 series
2021-003250-23Phase 3
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of cannabidiol in tuberous sclerosis complex (TSC), Sanfilippo syndrome, Fragile X syndrome (FXS) and 2 more, sponsored by Amsterdam University Medical Center. Primary endpoint: Irritability subscale of the Aberrant Behavior Checklist (ABC).
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)Sanfilippo syndromeFragile X syndrome (FXS)Autism Spectrum Disorder (ASD)behavioral disorder
Beyond the preview
Go deeper on 2021-003250-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003250-23.